Stocks Health care CANF
NYSE · Health careCan-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd. reported revenue of $405K in fiscal 2025, down 39.9% from a year earlier. It posted a net loss of $9.8M. In fiscal 2025 capital spending exceeded operating cash flow by $9M. At December 31, 2025 it held $5.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 26, 2026.
What Can-Fite BioPharma Ltd. does
Can-Fite BioPharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker CANF.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $405K | -$9.8M | -$5.97 | -$9M |
| 2024 | $674K | -$7.9M | -$10.86 | -$7.6M |
| 2023 | $743K | -$7.6M | -$17.92 | -$8.4M |
| 2022 | $810K | -$10.2M | -$17.92 | -$10.8M |
| 2021 | $853K | -$12.6M | -$53.76 | -$9.9M |
| 2020 | $763K | -$14.4M | -$71.68 | -$12.1M |
Where CANF ranks in Health care
Dividends
It paid out $2.6M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2021 | n/a | $2.6M | n/a |
| 2020 | n/a | $715K | n/a |
Latest SEC filings
What Can-Fite BioPharma Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026Form F-3/A filing F-3/A
- September 9, 2026
- September 8, 2026Form POS AM filing POS AM
- September 8, 2026Form POS AM filing POS AM
- September 8, 2026
- September 3, 2026
- September 2, 2026
- September 2, 2026
- August 28, 2026Form F-3 filing F-3
- August 17, 2026
Insider trades
What the people running Can-Fite BioPharma Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about CANF
What does Can-Fite BioPharma Ltd. do?
Can-Fite BioPharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker CANF.
Is Can-Fite BioPharma Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $9.8M on revenue of $405K.
How much revenue does Can-Fite BioPharma Ltd. make?
In fiscal 2025 Can-Fite BioPharma Ltd. reported revenue of $405K. That is 39.9% less than a year earlier.
When did Can-Fite BioPharma Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 26, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the form F-3/A filing from September 25, 2026.
Similar companies
Compare CANF with
Follow CANF
Get an email when Can-Fite BioPharma Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CANF: get an email when it filesWhere the numbers come from
Financial figures are the values Can-Fite BioPharma Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.